罗沙司他治疗维持性腹膜透析患者肾性贫血的临床效果和对心功能的影响

The clinical effect of rosastatin on renal anemia and its influence on cardiac function in patients performing peritoneal dialysis

目的探讨罗沙司他治疗腹膜透析(CAPD)患者肾性贫血的临床疗效和对心功能的影响。方法选取2018年4月至2021年4月于本院治疗的50例CAPD肾性贫血患者作为研究对象,按照系统抽样方法分为对照组与观察组,各25例。两组均行CAPD,对照组采用促红细胞生成素(EPO)、琥珀酸亚铁缓释片治疗,观察组采用罗沙司他治疗,比较两组治疗前后贫血指标[血红蛋白(Hb)、红细胞压积(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)]及心功能指标[B型脑钠肽(BNP)、降钙素原(PCT)、左心室舒张末期内径(LVEDd)、左心室射血分数(LVEF)]、心血管不良事件发生率。结果治疗前,两Hb、HCT、SF、TSAT水平比较差异无统计学意义;治疗后,两组Hb、HCT、SF、TSAT水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组BNP、PCT、LVEDd、LVEF比较差异无统计意义;治疗后,两组BNP、PCT水平均低于治疗前,LVEDd均短于治疗前,LVEF均高于治疗前,且观察组BNP、PCT水平均低于对照组(P<0.05),两组治疗后LVEDd、LVEF比较差异无统计学意义。观察组心血管不良事件发生率低于对照组,差异有统计学意义(P<0.05)。结论罗沙司他可明显改善CAPD患者的肾性贫血及心功能,减少心血管不良事件的发生,对CAPD肾性贫血患者具有良好的临床应用价值。

Objective To investigate the clinical efficacy of rosastatin on the treatment of renal anemia and its effect on cardiac function in patients performing peritoneal dialysis.Methods 50 patients with peritoneal dialysis renal anemia treated in our hospital from April 2018 to April 2021 were selected as the study subjects,and they were divided into the control group and the observation group according to systematic sampling method,with 25 cases in each group.Both groups underwent peritoneal dialysis,the control group was treated with erythropoietin(EPO)and ferrous succinate sustained-release tablets,while the observation group was treated with rosastatin,the anemia indicators(hemoglobin[Hb],hematocrit[HCT],serum Ferritin[SF],transferrin saturation[TSAT])and cardiac function indicators(B-type brain natriuretic peptide[BNP],procalcitonin[PCT],left ventricular end diastolic dimension[LVEDd],left ventricular ejection fraction[LVEF])before and after treatment,and the incidence of cardiovascular adverse events were compared between the two groups.Results Before treatment,there was no significant difference in Hb,HCT,SF and TSAT levels between the two groups;after treatment,Hb,HCT,SF and TSAT levels of the two groups were higher than before treatment,and the observation group was higher than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in BNP,PCT,LVEDd and LVEF between the two groups;after treatment,the levels of BNP and PCT of the two groups were lower than before treatment,the LVEDd was shorter than before treatment,the LVEF was higher than before treatment,and the levels of BNP and PCT in the observation group were lower than the control group,and the differences were statistically significant(P<0.05);there was no significant difference in LVEDd and LVEF between the two groups after treatment.The incidence of cardiovascular adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Rosastatin can significantly improve renal anemia and cardiac function in peritoneal dialysis patients,reduce the incidence of cardiovascular adverse events,rosastatin has good clinical application value in peritoneal dialysis patients with renal anemia.